UCSD SOBQ scores in pirfenidone trial and during extension trial. This figure presents the UCSD SOBQ scores at baseline, 6 months, 12 months, and during the extension phase (12-56 months) of the Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome trial. The UCSD SOBQ consists of 24 questions, each scored on a scale from 0 to 5, with total scores ranging from 0 to 120. Higher scores indicate more severe shortness of breath. (A) Breathlessness score: assessed by 21 questions focusing on the severity of shortness of breath during activities of daily living. (B) Total shortness of breath score: includes the breathlessness score plus 3 additional questions that evaluate fear related to limitations. The data are presented as mean scores with the standard error of the mean. A MCID, denoted by #, is defined as a reduction of >5 points from baseline.
Figure 6.

UCSD SOBQ scores in pirfenidone trial and during extension trial. This figure presents the UCSD SOBQ scores at baseline, 6 months, 12 months, and during the extension phase (12-56 months) of the Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome trial. The UCSD SOBQ consists of 24 questions, each scored on a scale from 0 to 5, with total scores ranging from 0 to 120. Higher scores indicate more severe shortness of breath. (A) Breathlessness score: assessed by 21 questions focusing on the severity of shortness of breath during activities of daily living. (B) Total shortness of breath score: includes the breathlessness score plus 3 additional questions that evaluate fear related to limitations. The data are presented as mean scores with the standard error of the mean. A MCID, denoted by #, is defined as a reduction of >5 points from baseline.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal